Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Stem-cell-based therapy is a promising new approach to handling neurodegenerative diseases. One of the most promising cellular sources is bone-marrow-derived mesenchymal stem cells (MSCs) also termed multipotent stromal cells. MSCs represent an autologous source and are abundant and non-tumorigenic. Additionally, MSCs possess the useful characteristics of homing and chemokine secretion. OBJECTIVE/METHODS: Since neurodegenerative diseases have many pathological processes in common, a specific therapeutic agent could potentially ameliorate the symptoms of several distinct neurodegenerative diseases. In this review we demonstrate the wide variety of mechanisms by which MSCs can influence neurodegenerative processes. RESULTS/CONCLUSIONS: The mechanisms by which transplanted MSCs influence neurodegenerative diseases can be broadly classified as cellular replacement or paracrine secretion, with the latter subdivided into trophic factor secretion or immunomodulation by cytokines. Emerging research suggests that genetic manipulations before transplantation could enhance the therapeutic potential of MSCs. Such manipulation could turn the cells into a 'Trojan horse', to deliver specific proteins, or promote reprogramming of the MSCs into the neural lineage. Clinical trials testing MSC-based therapies for familial amyotrophic lateral sclerosis and multiple sclerosis are in progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722 · cited 1×
“The replacement cells are either differentiated stem cells [15-17] or post-mitotic fetal grafts [18-20].”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417 · cited 1×
“Moreover, MSCs have been reported to migrate towards tumors in vivo, raising the possibility that they can serve as novel vectors for anti-tumor agents [100,101].”
BackgroundAdult human mesenchymal stem cell as a target for neoplastic transformation
Serakinci, N., Guldberg, P., Burns, J. S., Abdallah, B., Schrødder, H., Jensen, T., & Kassem, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207651 · Cited by 350 · cited 1×
“Recent studies have demonstrated that MSC that are cultured for a very long period can exhibit some neoplastic transformation towards what seems to be cancer stem cells, either spontaneously [119] or in immortalized MSCs by expression telomerase reverse transcriptase [120].”
Background
Cited by
Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes
Katsuda, T., Tsuchiya, R., Kosaka, N., Yoshioka, Y., Takagaki, K., Oki, K., Takeshita, F., Sakai, Y., Kuroda, M., & Ochiya, T. (2013) · Scientific Reports · doi:10.1038/srep01197 · Cited by 565
Petrou, P., Gothelf, Y., Argov, Z., Gotkine, M., Levy, Y. S., Kassis, I., Vaknin-Dembinsky, A., Ben-Hur, T., Offen, D., Abramsky, O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4321 · Cited by 303
Self-citationEngineered nanoparticles for biomolecular imaging
Mahmoudi, M., Serpooshan, V., & Laurent, S. (2011) · Nanoscale · doi:10.1039/c1nr10326a · Cited by 262
Concise Review: Mesenchymal Stem Cells in Neurodegenerative Diseases
Volkman, R., & Offen, D. (2017) · Stem Cells · doi:10.1002/stem.2651 · Cited by 222
Self-citationMesenchymal stem cell transplantation in multiple sclerosis
Cohen, J. A. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.12.009 · Cited by 127
“The immunomodulatory, tissue protective, and repair-promoting properties of MSCs described below make them an attractive potential therapy for MS and other neurologic disorders [7–10].”
Background
Metadata
- Authors
- Sadan, O., Melamed, E., & Offen, D.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa Healthcare
- Published
- 2009-10-13
- Volume
- 9
- Issue
- 12
- Pages
- 1487-1497
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2122491860
- Cited by
- 116
- References
- 6
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. https://app.cochat.ai/papers/10.1517/14712590903321439
- The paper
- Sadan, O., Melamed, E., & Offen, D. (2009). Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712590903321439
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.